MadeMed review

MadeMed's pitch is a single number per medicine. On its own product pages, injectable semaglutide is $239 a month at 0.25mg and still $239 at 2.4mg; injectable tirzepatide is $399 a month from 2.5mg through 15mg. The company explains why in its FAQ: when prices climb with each dose, every titration call becomes a revenue decision, and it wants its doctors out of that math. For a reader planning past the first two months, that matters more than an intro rate, because the dose you end up on is usually the expensive part elsewhere.

The trade is commitment. There is no month-to-month option on these pages. The quarterly plan bills $717 every three months for semaglutide and $1,197 for tirzepatide; the six-month plan lowers the monthly rate by $40 for semaglutide (to $199) and $30 for tirzepatide (to $369). One vial arrives every two months, with L-carnitine mixed in, syringes and swabs included, and overnight shipping in cold packaging at no charge. Doses only go up when you ask and the care team approves it, no sooner than about every four weeks.

Two tablet options sit beside the shots: oral semaglutide with vitamin B6 at $219 a month quarterly (from $179 on six months), and oral tirzepatide at $299 (from $279). These are sublingual tablets you dissolve under the tongue, shipped 60 at a time. Everything MadeMed sells for weight loss is compounded, so none of it is FDA-approved, and there is no route to Wegovy or Zepbound.

Check your state before anything else. The injection FAQs list 23 states, including Texas, Florida, Illinois and New York, while the tablets reach 40 states but skip Alabama, Alaska, Arkansas, Hawaii, Massachusetts, Missouri, New Mexico, New York, South Carolina and Virginia. A New Yorker can get the shot but not the tablet; someone in California, Ohio or Pennsylvania appears to be limited to the tablets.